UC and UC Health are hosting a Phase 3 clinical trial to evaluate the effectiveness of a vaccine for COVID-19. UC is one of 90 sites across the United States selected for the study, which will administer the vaccine to volunteer participants and monitor its efficacy in eliciting an immune response that provides protection from COVID-19. The study is led by Carl Fichtenbaum, MD, and Maggie Powers-Fletcher, PhD, both of the UC College of Medicine Division of Infectious Diseases.
Other coverage:
/University Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
